The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ADMA | -13.5% | +901.09% | +58.52% | +115% |
| S&P | +12.33% | +84.73% | +13.06% | +284% |
ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $134.22M | 12.0% |
| Gross Profit | $75.59M | 26.8% |
| Gross Margin | 56.31% | 6.6% |
| Market Cap | $3.50B | -24.9% |
| Market Cap / Employee | $5.11M | 0.0% |
| Employees | 685 | 9.8% |
| Net Income | $36.43M | 1.4% |
| EBITDA | $53.04M | 27.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $61.39M | -29.2% |
| Accounts Receivable | $137.67M | 174.6% |
| Inventory | 196.7 | 14.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $79.48M | -27.9% |
| Short Term Debt | $3.64M | 205.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 43.67% | 25.2% |
| Return On Invested Capital | -11.22% | 17.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1.08M | -104.5% |
| Operating Free Cash Flow | $13.29M | -46.9% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 21.19 | 23.50 | 21.44 | 17.22 | -76.20% |
| Price to Book | 17.48 | 13.45 | 11.63 | 8.81 | -56.76% |
| Price to Sales | 9.89 | 10.57 | 9.55 | 7.34 | -42.57% |
| Price to Tangible Book Value | 17.79 | 13.61 | 11.76 | 8.90 | -57.07% |
| Price to Free Cash Flow TTM | 38.18 | 53.56 | 68.83 | 88.07 | 42.87% |
| Enterprise Value to EBITDA | 104.21 | 132.02 | 100.78 | 68.04 | -42.48% |
| Free Cash Flow Yield | 2.6% | 1.9% | 1.5% | 1.1% | -30.01% |
| Return on Equity | 81.6% | 78.5% | 71.2% | 63.2% | 77.72% |
| Total Debt | $82.12M | $82.01M | $83.83M | $83.12M | -25.37% |
No podcast episodes available.
ADMA earnings call for the period ending September 30, 2021.
ADMA earnings call for the period ending June 30, 2021.
ADMA earnings call for the period ending March 31, 2021.
ADMA earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
